BMEA:NSD-Biomea Fusion Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 10.99

Change

0.00 (0.00)%

Market Cap

USD 0.32B

Volume

0.09M

Avg Analyst Target

USD 26.33 (+139.61%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is headquartered in Redwood City, California. Address: Chamberlain Building, Redwood City, CA, United States, 94063

Company Website : http://www.biomeafusion.com

Address : Chamberlain Building, Redwood City, CA, United States, 94063

Employees : 20

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 22.22

Short Ratio : 20.90

52 Week Low : 9.72

Shorted Shares : 1,638,413

200 Day Moving Average : 14.58

Shorted Shares Previous Month : 1,437,168

50 Day Moving Average : 11.55

Shares Held By Insiders : 33.54%

Short Percentage : 6.00%

Shares Held by Institutions : 58.68%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

 USD131.81B 38.58 31.39
BNTX BioNTech SE

N/A

 USD67.50B 15.50 10.94
REGN Regeneron Pharmaceuticals Inc

N/A

 USD61.22B 10.34 7.53
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD47.61B 24.20 15.87
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BGNE BeiGene Ltd

N/A

 USD35.36B N/A N/A
SGEN Seagen Inc

N/A

 USD31.19B 53.49 43.63
GMAB Genmab A/S

N/A

 USD30.55B 78.60 8.55
ALNY Alnylam Pharmaceuticals Inc

N/A

 USD23.60B N/A N/A
RPRX Royalty Pharma plc

N/A

 USD22.77B 30.36 12.47

ETFs Containing BMEA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.32B 49% F 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.67 81% B- 67% D+
Price / Cash Flow Ratio -71.47 93% A 89% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -17.49% 87% B+ 41% F
Return on Invested Capital -205.52% 6% F 3% F
Return on Assets -10.60% 84% B 28% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 20.90 3% F 1% F
Short Percent 10.77% 17% F 16% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.